Literature DB >> 12451320

Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure.

Makoto Hikosaka1, Fumio Yuasa, Reisuke Yuyama, Jun Mimura, Akihiro Kawamura, Masayuki Motohiro, Masayoshi Iwasaki, Tetsuro Sugiura, Toshiji Iwasaka.   

Abstract

The purpose of this study was to investigate the effects of candesartan on arterial baroreflex sensitivity (BRS) and sympathetic activity in patients with mild heart failure (HF). Arterial pressure, heart rate, plasma renin activity, plasma angiotensin II and noradrenaline, and muscle sympathetic nerve activity (MSNA) were measured before therapy and after 4 weeks in 20 patients with mild HF. Patients were assigned to a candesartan group (n = 10) or a placebo group (n = 10). Baroreflex sensitivity was assessed by using phenylephrine. Candesartan induced an increase in plasma renin activity and plasma angiotensin II associated with a reduction in arterial pressure without affecting heart rate. Although plasma noradrenaline was unchanged (320 +/- 322 pg/ml to 339 +/- 104 pg/ml), MSNA decreased significantly (52 +/- 11 bursts/min to 42 +/- 9 bursts/min; p < 0.01)) and BRS increased significantly (6.9 +/- 3.6 msec/mm Hg to 10.2 +/- 3.3 msec/mm Hg; p < 0.01) after candesartan. However, there were no significant changes in the measured variables in the placebo group. These data indicate that candesartan treatment enhanced BRS and reduced sympathetic activity in patients with mild HF. Thus, the inhibitory effect of candesartan on sympathetic activity may, at least in part, contribute to the beneficial effect of angiotensin II receptor blockade in patients with mild HF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12451320     DOI: 10.1097/00005344-200212000-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.

Authors:  John S Floras; Piotr Ponikowski
Journal:  Eur Heart J       Date:  2015-05-13       Impact factor: 29.983

2.  Response of cardiac sympathetic nerve activity to intravenous irbesartan in heart failure.

Authors:  Rohit Ramchandra; Anna M D Watson; Sally G Hood; Clive N May
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-02-10       Impact factor: 3.619

3.  Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial.

Authors:  Tamara B Horwich; Holly R Middlekauff; W Robb Maclellan; Gregg C Fonarow
Journal:  J Card Fail       Date:  2011-09-03       Impact factor: 5.712

Review 4.  Angiotensin receptor blockers for heart failure.

Authors:  Balraj S Heran; Vijaya M Musini; Ken Bassett; Rod S Taylor; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 5.  Angiotensin II, sympathetic nerve activity and chronic heart failure.

Authors:  Yutang Wang; Sai-Wang Seto; Jonathan Golledge
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

6.  Potential autonomic nervous system effects of statins in heart failure.

Authors:  Tamara B Horwich; Holly R Middlekauff
Journal:  Heart Fail Clin       Date:  2008-04       Impact factor: 3.179

7.  Reverse re-modelling chronic heart failure by reinstating heart rate variability.

Authors:  J Shanks; Y Abukar; N A Lever; M Pachen; I J LeGrice; D J Crossman; A Nogaret; J F R Paton; R Ramchandra
Journal:  Basic Res Cardiol       Date:  2022-02-01       Impact factor: 12.416

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.